EFPIA objects to ‘pressure’ from EMA over theoretical medicines shortages
This article was originally published in Scrip
EFPIA, the federation of R&D-based industry associations, is using concern about the impact of forthcoming legislation on drug shortages to call for the European Medicines Agency to look more closely the impact of low prices. EFPIA is warning the agency that it must find a pragmatic way to implement the highly problematic Falsified Medicines Directive.
You may also be interested in...
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.
Better dialogue with companies, together with new regulations and ways of working, have helped Brazil’s medicines regulator set new records for registering pharmaceuticals.